Total submissions: 33
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000113272 | SCV000245030 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-01-12 | reviewed by expert panel | curation | Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.02236 (African), derived from 1000 genomes (2012-04-30). |
Invitae | RCV000044344 | SCV000072357 | benign | Hereditary breast ovarian cancer syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000131014 | SCV000185940 | benign | Hereditary cancer-predisposing syndrome | 2014-07-29 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Michigan Medical Genetics Laboratories, |
RCV000113272 | SCV000195981 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-04-21 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000113272 | SCV000220319 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-05-14 | criteria provided, single submitter | literature only | |
Eurofins Ntd Llc |
RCV000120319 | SCV000225186 | benign | not specified | 2014-07-16 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000113272 | SCV000383693 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2018-11-01 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV000389513 | SCV000383694 | likely benign | Fanconi anemia complementation group D1 | 2018-11-01 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000044344 | SCV000494323 | benign | Hereditary breast ovarian cancer syndrome | 2014-04-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000469910 | SCV000541050 | benign | Familial cancer of breast | 2017-02-23 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000120319 | SCV000593715 | benign | not specified | 2017-11-08 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000656601 | SCV000602753 | benign | not provided | 2022-04-04 | criteria provided, single submitter | clinical testing | |
Institute for Biomarker Research, |
RCV000131014 | SCV000679717 | likely benign | Hereditary cancer-predisposing syndrome | 2017-07-12 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000131014 | SCV000683601 | benign | Hereditary cancer-predisposing syndrome | 2015-03-06 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000113272 | SCV000743295 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2017-07-28 | criteria provided, single submitter | clinical testing | |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000113272 | SCV000744451 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2017-05-31 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000120319 | SCV000805704 | benign | not specified | 2016-11-22 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000770724 | SCV000902203 | benign | Breast and/or ovarian cancer | 2016-03-08 | criteria provided, single submitter | clinical testing | |
National Health Laboratory Service, |
RCV000044344 | SCV002026099 | benign | Hereditary breast ovarian cancer syndrome | 2022-04-19 | criteria provided, single submitter | clinical testing | |
Genetics Program, |
RCV000044344 | SCV002515270 | benign | Hereditary breast ovarian cancer syndrome | 2021-11-01 | criteria provided, single submitter | research | |
KCCC/NGS Laboratory, |
RCV000113272 | SCV004016861 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Center for Genomic Medicine, |
RCV000120319 | SCV004243027 | benign | not specified | 2024-02-06 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000113272 | SCV004845269 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2024-02-05 | criteria provided, single submitter | clinical testing | |
ITMI | RCV000120319 | SCV000084471 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Breast Cancer Information Core |
RCV000113272 | SCV000146371 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2002-05-29 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000113272 | SCV000591890 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | no assertion criteria provided | clinical testing | The p.Ile1364Leu variant has been previously observed in our laboratory, and has been reported in the literature in 11/2200 proband chromosomes of individuals with breast cancer. However, no controls were tested to establish the frequency of the variant in the general population (Borg_2010_, Caux-Moncoutier_2009_, Haffty_2006_, Haffty_2009_, Tazzite_2012_). It is listed in the dbSNP database as coming from a "clinical source" (ID#:rs56248502) with a global minor allele frequency (MAF) of 0.005 (1000 Genomes). The variant has been reported in the UMD (x17), BIC (x53) and CNPHI databases. In the UMD database, the variant was observed to co-occur with other BRCA2 pathogenic mutations: c.6159delT (p.Ala2054LeufsX16) and c.8548_8551delGAAG (p.Glu2850GlnfsX12), increasing the likelihood that the p.Ile1364Leu variant does not have any clinical significance. This residue is not conserved in mammals and computational analyses (PolyPhen, SIFT, AlignGVGD) do not suggest a high likelihood of impact to the protein. However, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information, the p.Ile1364Leu variant is classified as benign. | |
Diagnostic Laboratory, |
RCV000113272 | SCV000733253 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | no assertion criteria provided | clinical testing | ||
Mayo Clinic Laboratories, |
RCV000656601 | SCV000778671 | likely benign | not provided | 2017-08-09 | no assertion criteria provided | clinical testing | |
True Health Diagnostics | RCV000131014 | SCV000787929 | likely benign | Hereditary cancer-predisposing syndrome | 2018-01-03 | no assertion criteria provided | clinical testing | |
Clinical Genetics Laboratory, |
RCV000120319 | SCV001906090 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000120319 | SCV001958655 | benign | not specified | no assertion criteria provided | clinical testing | ||
Laboratory of Diagnostic Genome Analysis, |
RCV000120319 | SCV002035773 | benign | not specified | no assertion criteria provided | clinical testing | ||
BRCAlab, |
RCV000113272 | SCV004243621 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2020-03-02 | no assertion criteria provided | clinical testing |